Montrouge, France, March 7, 2024
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
* Advanced Viaskin(TM) Peanut clinical development programs in peanut-allergic

    toddlers (1 through 3 years old) and children (4 through 7 years old)
  * Strengthened executive leadership team in preparation for BLA submission
  * Reported cash and cash equivalents of $141 million

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023. The audit
procedures have been substantially completed by the Company's statutory auditors
and financials - prepared under both US GAAP and IFRS for the purpose of Form 10-K and Universal Registration Document respectively - were approved by the Board of Directors on March 7, 2024.
"During 2023, we made significant progress advancing our two Viaskin Peanut clinical development programs in two distinct age groups, one for toddlers ages 1 to 3 years, and one for children ages 4 to 7 years," said Daniel Tassé, Chief Executive Officer of DBV Technologies. "In 2024, we are focused on completing enrollment in VITESSE, our Phase 3 efficacy and safety trial in children. Despite the delays experienced as a result of the new European Commission directive on Clinical Trials Regulation, all countries are open and actively recruiting. We expect good momentum regarding Vitesse recruitment in the next several months and last subject screened by Q3 2024.
In addition, we are initiating two supplemental six-month safety trials, COMFORT
Toddlers and COMFORT Children, as the final clinical pieces to support two separate and robust packages for our Biologics License Applications to the FDA."
Mr. Tassé continued, "We are committed to working as swiftly and diligently as possible to bring this novel treatment option to market for toddlers and children and their families who are living with the daily and significant burden
of a peanut allergy."
2023 Operational Highlights
* Confirmed EPITOPE, DBV's Phase 3 efficacy and safety study of Viaskin Peanut in peanut-allergic toddlers aged 1 through 3 years, is sufficient for the
clinical portion of a BLA, and no additional efficacy studies were requested

    by the FDA.
  * Prepared for initiation of COMFORT Toddlers and COMFORT Children, including
    protocol development for both supplemental six-month safety studies.
      * Number of participants on active treatment will total approximately 600

children in each of the two BLAs, 1 to 3-year-olds and 4 to 7-year-olds.

  * Implemented simplified protocol language for both COMFORT Toddlers and
    COMFORT Children indicating that Viaskin Peanut is "intended to be worn for
    a full day" with any reference to minimum wear time removed.
  * Initiated VITESSE, a Phase 3 clinical trial to evaluate the efficacy and

safety of the circular Viaskin Peanut patch in peanut-allergic children aged

    4 through 7 years and activated more than 85 trial sites across North
    America, Australia and Europe.
  * Published EPITOPE results (https://dbv-technologies.com/press_releases/dbv-

technologies-announces-new-england-journal-of-medicine-publication-of-phase-

    3-epitope-trial-data-evaluating-viaskin-peanut-in-toddlers/) in the New
    England Journal of Medicine with an accompanying editorial, entitled, Good
    News for Toddlers with Peanut Allergy.
  * Presented interim safety and efficacy data from the open-label extension of
    EPITOPE (https://dbv-technologies.com/wp-
    content/uploads/2023/11/Greenhawt_ACAAI_EPOPEX-Year-1_FINAL-v3.0-
    08Nov2023.pdf), which demonstrate a robust continued treatment effect with
    Viaskin Peanut after two years of treatment, at The American College of
    Allergy, Asthma, and Immunology annual meeting.
  * Strengthened the executive leadership team with the appointment of Virginie
    Boucinha as Chief Financial Officer and Dr. Kevin Malobisky, PhD., as Chief
    Operations Officer.

Anticipated 2024 Events

  * Initiate COMFORT Toddlers, the six-month supplemental safety trial in
    support of BLA.
  * Screen last patient in VITESSE, now expected by Q3 2024.
  * Initiate COMFORT Children, the six-month supplemental safety trial in
    support of BLA.
  * Announce top-line efficacy and safety data from year three of EPITOPE,
    corresponding to end-of-study results for participants completing three
    years of active treatment.
  * Publish manuscripts including invited reviews in peer-reviewed scientific
    journals and submit abstracts on new data at upcoming scientific
    conferences.

Financial Highlights for the Full Year 2023
2023 Financial Highlights are presented under both U.S GAAP and IFRS. Financial statements comments refer to U.S. GAAP financial statements.
Differences between US GAAP and IFRS consolidated financial statements result mainly from the discrepancies arising from the application of lease accounting standards.
Cash and cash equivalents totaled $141.4 million as of December 31, 2023,
compared to $209.2 million as of December 31, 2022, a net decrease of $67.8 million.
* Overall, the Company used $79.6 million of cash in operations, primarily in
Research and Development, with the initiation of the VITESSE trial, with the

    first patient screened in March 2023, preparation activities related to
    COMFORT studies, as well as an increase in regulatory and pre-
    commercialization activities. Cash used in operations increased by $23.9
    million as of December 2023 compared to December 2022.
  * Cash provided by financing activities decreased by $187.4 million in 2023,
    compared to 2022. In June of 2022, the Company had completed a private
    placement financing ("PIPE") which raised total net proceeds of $194.4
    million. The net proceeds from the issuance and sale of new ordinary shares

in the form of American Depositary Shares ("ADSs") on June 16, 2023, totaled

    $6.9 million.
  * The Company also benefitted from a favorable exchange rate in the amount of
    $5.9 million.

Operating income amounts to $15.7 million as of December 31, 2023, an increase of $10.9 million compared to $4.8. million as of December 31, 2022, mainly due to:

  * A $7.8 million increase in other operating income from revenues recognized
    as part of the Development, Collaboration, and Licensing Agreement with
    Nestlé Health Science (the "Nestlé Collaboration Agreement"), which
    terminated on October 30(th), 2023.
  * Research Tax Credit increase by $3.0 million. As of December 31, 2023, the
    Company filed an additional research tax credit claim for the years
    2020, 2021 and 2022.

Operating income, excluding revenues from the Nestlé, Collaboration, Agreement amounts to $8.8 million.
Operating expenses amount to $92.2 million as of December 31, 2023, compared to $101.5 million as of December 31, 2022, a decrease of $9.3 million due to:
(1) A $15.3 million decrease in Research and Development expenses, composed of:
a. A $30.7 million favorable impact due to the termination of Nestlé

    Collaboration Agreement (primarily the reversal of the loss on completion
    accrual by $17.6 million in 2023 compared to a $10.4 million loss on
    completion accrual as of December 31(st), 2022).

b. An increase of $15.4 million in Research and Development expenses reflecting
intensified Research and Development activities following the initiation of
the VITESSE trial, with the first patient screened in March 2023, as well as preparations for COMFORT.
(2) A $5.2million increase in General and Administrative expenses, primarily due to $2.8 million in external services fees incurred in the Company's financing activities.
(3) A $0.8 million increase in Sales and Marketing expenses related to pre- commercialization activities for Viaskin Peanut in North America.
Operating expenses totaled $107.3 million as of December 31, 2023. when excluding the loss on completion accrual reversal from the Nestlé Collaboration Agreement.
DBV recorded a net loss of $72.7 million as of December 31, 2023, compared to a net loss of $96.3 million as of December 31, 2022.
On a per share basis, net loss (based on the weighted average number of shares outstanding over the period) is $0.76 as of December 31, 2023.
Excluding the Nestlé Collaboration Agreement termination, net loss as of December 31, 2023, would amount to $94.7 million.
The Company has incurred operating losses and negative cash flows from operations since inception. As of the date of the filing, the Company's available cash and cash equivalents are not projected to be sufficient to support its operating plan for at least the next 12 months. As such, there is substantial doubt regarding the Company's ability to continue as a going concern.
Based on current operations, as well as plans and assumptions, the Company expects that its balance of cash and cash equivalents of $141,4 million as of December 31, 2023, will be sufficient to fund its operations until December 31,2024.
The Company intends to seek additional capital through debt and equity offerings
as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved.
Conference Call Information
DBV will host a live conference call and webcast today at 5:00 p.m. ET to discuss full year 2023 financial results and provide a business update. The conference call may be accessed by dialing:
? United States: 1-844-481-2866
? International: 1-412-317-1859
A webcast of the call will also be available under "Events" in the Investors section of the DBV Technologies website: https://dbv-technologies.com/investor- overview/events (https://dbv-technologies.com/events/dbv-technologies-to-report-
full-year-2023-financial-results-and-business-update/). A replay of the presentation will also be available on DBV's website after the event.
Cash and Cash Equivalents

                                         US GAAP                  IFRS
 In millions of USD                Year ended December     Year ended December
                                           31,                     31,
                                   2023       2022         2023       2022
                                 ----------------------- ----------------------

Net cash & cash equivalents at
the beginning of the period 209,2 77,3 209,2 77,3
Net increase/(decrease) in
cash & cash equivalents, of
which: (67,8) 131,9 (67,8) 131,9
Net cash flow used in
operating activities (79,6) (55,7) (77,6) (51,4)
Net cash flow used in
investing activities (0,8) (0,1) (0,8) (0,1)
Net cash flow provided by /
((used in) financing
activities 6,7 194,1 4,8 189,9
Effect of exchange rate
changes on cash & cash
equivalents 5,9 (6,5) 5,8 (6,5)
-------------------------------- ----------------------- ----------------------
Net cash & cash equivalents at
the end of the period 141,4 209,2 141.2 209,2
-------------------------------- ----------------------- ----------------------
Operating income

                                   US GAAP                    IFRS
 In millions of USD          Year ended December      Year ended December
                                     31,                      31,
                            2023 2022   Variation    2023 2022   Variation
                           ------------------------------------------------
 Research tax credit        8,8   5,7  +3,0  +53%    8,8   5,7  +3,0  +53%
 Other operating income     6,9  (0,9) +7,8  -896%   6,9  (0,9) +7,8  -896%
------------------------   ------------------------ -----------------------
 Operating income           15,7  4,8  +10,9 +225%   15,7  4,8  +10,9 +225%
------------------------   ------------------------ -----------------------

Operating expenses

                                         US GAAP                  IFRS
 In millions of USD                Year ended December     Year ended December
                                           31,                     31,
                                  2023 2022  Variation    2023 2022  Variation
                                 ----------------------------------------------
 Research & Development           60,2 75,5  -15,3 -20%   60,1 75,2  -15,1 -20%
 Sales & Marketing                2,4   1,6  +0,8  +52%   2,4   1,6  +0,8  +56%
 General & Administrative         29,5 24,3  +5,2  +21%   29,5 24,2  +5,2  +22%

-------------------------------- ----------------------- ----------------------
Total operating expenses 92,2 101,5 -9,3 -9% 92,0 101,0 -9,0 -9%
-------------------------------- ----------------------- ----------------------
including internal
compensation 29,2 24,0 +5,2 +22% 29,3 24,0 +5,3 +22%
-------------------------------- ----------------------- ----------------------
Net Loss and Net Loss per Share

                                    US GAAP                      IFRS
                            Year ended December 31,    Year ended December 31,
                             2023   2022  Variation     2023   2022  Variation
                           ----------------------------------------------------

Net (loss) in millions
of USD (72,7) (96,3) +23,5 -24% (72,7) (96,0) +23,1 -24%
Basic / diluted net
(loss) per share in USD (0,76) (1,24) +0,5 -38% (0,76) (1,24) +0,5 -38%
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing
treatment options for food allergies and other immunologic conditions with
significant unmet medical need. DBV is currently focused on investigating the
use of its proprietary technology platform, Viaskin(TM), to address food allergies,
which are caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening anaphylaxis.
Millions of people live with food allergies, including young children. Through
epicutaneous immunotherapy (EPIT(TM)), the Viaskin platform is designed to
introduce microgram amounts of a biologically active compound to the immune
system through intact skin. EPIT is a new class of non-invasive treatment that
seeks to modify an individual's underlying allergy by re-educating the immune
system to become desensitized to allergen by leveraging the skin's immune
tolerizing properties. DBV is committed to transforming the care of food
allergic people. The Company's food allergy programs include ongoing clinical
trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age)
and children (4 through 7 years of age).
DBV Technologies is headquartered in Montrouge, France, with North American operations in Basking Ridge, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit www.dbvtechnologies.com (http://www.dbvtechnologies.com) and engage with us on X (formerly Twitter) (https://twitter.com/DBVTechnologies) and LinkedIn (https://www.linkedin.com/company/dbv-technologies/).
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV's forecast of its cash runway, the therapeutic potential of Viaskin(TM) Peanut and EPIT(TM), designs of DBV's anticipated
clinical trials, DBV's planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, the ability of any of DBV's product candidates, if approved, to improve the lives of patients with food allergies, and the outcome of any litigation. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV's product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV's ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements in this press release can be found in DBV's regulatory filings with the French Autorité des Marchés Financiers ("AMF"), DBV's filings and reports with the U.S. Securities and Exchange Commission ("SEC"), including in DBV's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no
obligation to update or revise the information contained in this Press Release.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com (mailto:katie.matthews@dbv-technologies.com)
Media Contact
Aurora Krause
DBV Technologies
aurora.krause-ext@dbv-technologies.com (mailto:aurora.krause-ext@dbv- technologies.com)
Â